Using comprehensive immune profiling of PBMCs at the single cell level and unsupervised approach, we have been able to detect subsets of immune cells (T-bet+ B cells, CD206+ classical monocytes, pro-inflammatory NK cells) significantly increased in our cohort of early untreated MS patients compared to controls. The gene discussed is MRC1; the disease is myeloid sarcoma.